Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases Replicate will receive research ...
California biotech Replicate Biosciences will receive up to $550 million from Novo Nordisk in an alliance that aims to track down new drugs for obesity and diabetes. The partners will develop new ...
Replicate Inc., a startup making it easier for software teams to build artificial intelligence applications, today exited stealth mode and announced that it has secured $17.8 million in funding. The ...
Replicate, a startup that runs machine learning models in the cloud, today launched out of stealth with $17.8 million in venture capital backing; $12.5 million of the total came from a Series A led by ...
Replicate Bioscience and Novo Nordisk collaborate to develop srRNA-based therapies for obesity, type 2 diabetes, and cardiometabolic diseases. Novo Nordisk receives an exclusive worldwide license to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results